Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY CSIMC Recommends Listing of 9 Products Including Imusera; Recommendation Put on Hold for Ilaris
November 17, 2011
-
REGULATORY High Court Turns Down Iressa Compensation Appeal
November 16, 2011
-
REGULATORY 7-Drug Rule Should Be Relaxed or Eliminated to Promote GE Name Prescribing: Dr Adachi of CSIMC
November 16, 2011
-
BUSINESS Japan’s Jul-Sep 2011 Ethical Drug Market Grows 7.7%: IMS Japan
November 15, 2011
-
BUSINESS Otsuka Forms Alliance with Lundbeck in CNS Field
November 14, 2011
-
BUSINESS Top-3 GE Makers Report 10.4% Increase in Sales; Pace Down from Year Before
November 11, 2011
-
REGULATORY MHLW Proposes Raising GE Dispensing Rates to Receive Upper Premiums for GE Dispensing Systems
November 10, 2011
-
REGULATORY Applications for “Regulatory Strategy Consultation” Increasing Rapidly: Mr Isobe of PMDA
November 10, 2011
-
BUSINESS Operating Profit Rate for Top-4 Wholesalers Slips to 0.39% in April-September
November 9, 2011
-
BUSINESS Astellas, RIKEN to Explore, Jointly Develop Novel Drug Targets for AD
November 9, 2011
-
BUSINESS Towa Pharmaceutical Developing Lipitor Generic Version OD Tablets
November 9, 2011
-
BUSINESS Towa Pharmaceutical’s New Business Plan is “Groundwork for Future Progress”
November 8, 2011
-
BUSINESS Suzuken President Ota Says Wholesale Business Recovery Crucial
November 8, 2011
-
BUSINESS 8 of 10 Leading Drug Makers Report Declines in 1st-Half Sales
November 7, 2011
-
REGULATORY CSIMC Subcommittee Approves Proposal to Expand Range of Drugs Subject to Re-pricing
November 4, 2011
-
BUSINESS Eisai President Says Japan, China to Become Key Battlefields for Aricept
November 2, 2011
-
BUSINESS Marketing of Imusera, Telavic to Be Limited to Specialists at First: MTPC
November 2, 2011
-
BUSINESS DSP to Boost Domestic CNS Business for Early Maximization of Lonasen
November 1, 2011
-
BUSINESS Shionogi’s Strength in Japan Weakened by Slack US Results, Overall Sales Down 13.5% in Apr-Sept
November 1, 2011
-
BUSINESS DSP: Strong Yen Contributes to 5.6% Decline in Sales
November 1, 2011
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…